Arcturus Therapeutics Holdings (ARCT) EBIAT: 2018-2025
Historic EBIAT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Sep 2025 value amounting to -$13.4 million.
- Arcturus Therapeutics Holdings' EBIAT fell 94.81% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 6.49%. This contributed to the annual value of -$80.9 million for FY2024, which is 172.30% down from last year.
- Arcturus Therapeutics Holdings' EBIAT amounted to -$13.4 million in Q3 2025, which was down 46.49% from -$9.2 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' EBIAT's 5-year high stood at $117.3 million during Q4 2022, with a 5-year trough of -$56.3 million in Q1 2021.
- Over the past 3 years, Arcturus Therapeutics Holdings' median EBIAT value was -$14.1 million (recorded in 2025), while the average stood at -$13.4 million.
- Its EBIAT has fluctuated over the past 5 years, first tumbled by 476.31% in 2021, then skyrocketed by 403.51% in 2022.
- Over the past 5 years, Arcturus Therapeutics Holdings' EBIAT (Quarterly) stood at -$38.7 million in 2021, then skyrocketed by 403.51% to $117.3 million in 2022, then crashed by 109.98% to -$11.7 million in 2023, then slumped by 156.30% to -$30.0 million in 2024, then crashed by 94.81% to -$13.4 million in 2025.
- Its EBIAT was -$13.4 million in Q3 2025, compared to -$9.2 million in Q2 2025 and -$14.1 million in Q1 2025.